Discovery of a highly potent FLT3 kinase inhibitor for FLT3-ITD-positive AML-Reference-Cited by-同舟云学术

Discovery of a highly potent FLT3 kinase inhibitor for FLT3-ITD-positive AML

Published:2016-05-25 Issue:10 Volume:30 Page:2112-2116
ISSN:0887-6924
Container-title:Leukemia
language:en
Short-container-title:Leukemia

Author:

Wu H,Wang A,Qi Z,Li X,Chen C,Yu K,Zou F,Hu C,Wang W,Zhao Z,Wu J,Liu J,Liu X,Wang L,Wang W,Zhang S,Stone R M,Galinsky I A,Griffin J D,Weinstock D,Christodoulou A,Wang H,Shen Y,Zhai Z,Weisberg E L,Liu J,Liu Q

Publisher

Springer Science and Business Media LLC

Subject

Oncology,Cancer Research,Hematology

Link

http://www.nature.com/articles/leu2016151.pdf

Reference10 articles.

1. Lowenberg B, Downing JR, Burnett A . Acute myeloid leukemia. N Engl J Med 1999; 341: 1051–1062.

2. Markovic A, MacKenzie KL, Lock RB . FLT-3: a new focus in the understanding of acute leukemia. Int J Biochem Cell Biol 2005; 37: 1168–1172.

3. Smith CC, Wang Q, Chin CS, Salerno S, Damon LE, Levis MJ et al. Validation of ITD mutations in FLT3 as a therapeutic target in human acute myeloid leukaemia. Nature 2012; 485: 260–263.

4. Galanis A, Ma H, Rajkhowa T, Ramachandran A, Small D, Cortes J et al. Crenolanib is a potent inhibitor of FLT3 with activity against resistance-conferring point mutants. Blood 2014; 123: 94–100.

5. Zarrinkar PP, Gunawardane RN, Cramer MD, Gardner MF, Brigham D, Belli B et al. AC220 is a uniquely potent and selective inhibitor of FLT3 for the treatment of acute myeloid leukemia (AML). Blood 2009; 114: 2984–2992.

Cited by 12 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Recent advances in the development of RIPK2 modulators for the treatment of inflammatory diseases;Frontiers in Pharmacology;2023-03-07

2. Discovery of Potent and Selective Receptor-Interacting Serine/Threonine Protein Kinase 2 (RIPK2) Inhibitors for the Treatment of Inflammatory Bowel Diseases (IBDs);Journal of Medicinal Chemistry;2022-06-16

3. Molecular mechanisms by which splice modulator GEX1A inhibits leukaemia development and progression;British Journal of Cancer;2022-04-14

4. CD34+ CD38- subpopulation without CD123 and CD44 is responsible for LSC and correlated with imbalance of immune cell subsets in AML;BIOCELL;2022

5. Discovery of a Potent and Selective FLT3 Inhibitor (Z)-N-(5-((5-Fluoro-2-oxoindolin-3-ylidene)methyl)-4-methyl-1H-pyrrol-3-yl)-3-(pyrrolidin-1-yl)propanamide with Improved Drug-like Properties and Superior Efficacy in FLT3-ITD-Positive Acute Myeloid Leukemia;Journal of Medicinal Chemistry;2021-04-02